Highlights
In four population-based diabetes cohorts from Australia, the United States, Mauritius, and India, younger adults with type 2 diabetes generally had higher BMI and more adverse lipid profiles, especially higher triglycerides, than older adults.
Markers of glycemia did not worsen monotonically with age. Fasting plasma glucose and HbA1c tended to peak in midlife, then decline at older ages, suggesting that hyperglycemia-related risk may be especially prominent earlier in the disease course for many adults.
Older adults had higher systolic blood pressure and urinary albumin/creatinine ratio, consistent with greater vascular and renal burden with advancing age.
Compared with people with normal glucose tolerance, the excess burden of fasting glucose, HbA1c, triglycerides, and diastolic blood pressure associated with diabetes was generally greater at younger ages than at older ages.
Background
Type 2 diabetes is increasingly diagnosed at younger ages worldwide, and younger-onset disease has emerged as a major clinical challenge. Prior work has shown that adults diagnosed earlier in life often face a higher lifetime risk of microvascular and macrovascular complications, premature cardiovascular disease, and early mortality. Longer exposure to hyperglycemia is one obvious explanation, but it is unlikely to be the only one.
The study by Sajjadi and colleagues addresses an important question: do younger adults with type 2 diabetes also carry a distinct and potentially more adverse cardiometabolic phenotype than older adults? This matters clinically because the risk of complications in diabetes is not determined by glucose alone. Adiposity, dyslipidemia, blood pressure, and kidney injury markers all shape long-term outcomes, and these factors may cluster differently across the age spectrum.
The clinical relevance is substantial. If younger adults with diabetes have a pattern characterized by severe obesity, atherogenic dyslipidemia, and marked glycemic separation from age-matched peers without diabetes, then management strategies built primarily around age-based cardiovascular risk may underestimate lifetime hazard. Conversely, if older adults have greater blood pressure elevation and albuminuria, priorities may need to shift toward renal and vascular protection in later life.
Proposed Article Structure
This article first summarizes the study design and multinational cohorts, then reviews the major age-related trends in adiposity, lipids, glycemia, blood pressure, and albuminuria. It next interprets these findings in relation to complication biology and clinical management, followed by a discussion of limitations, implications for practice, and key research gaps.
Study Design
Design and data sources
This was a cross-sectional analysis of national health survey data from four countries spanning diverse ethnic and socioeconomic settings:
Australian Diabetes, Obesity and Lifestyle Study (AusDiab); US National Health and Nutrition Examination Survey (NHANES); Mauritius Non-Communicable Diseases Survey; and Indian Council of Medical Research-India Diabetes (ICMR-INDIAB) study.
Population
The analysis included adults with type 2 diabetes, comprising both previously diagnosed diabetes and newly diagnosed, screen-detected diabetes. People with normal glucose tolerance were also included as a comparator group to determine whether diabetes-related risk-factor differences varied by age.
Sample sizes were substantial: 903 participants with type 2 diabetes in AusDiab, 7086 in NHANES, 2682 in the Mauritius Survey, and 10,151 in ICMR-INDIAB.
Exposure and outcomes
The primary exposure was age at survey. The main outcomes were cardiometabolic risk factors relevant to diabetes complications, including BMI, LDL cholesterol, HDL cholesterol, triglycerides, fasting plasma glucose, 2-hour plasma glucose in newly diagnosed diabetes, HbA1c, systolic and diastolic blood pressure, and urinary albumin/creatinine ratio.
Statistical approach
The investigators used regression models with natural splines to examine non-linear associations between age and each risk factor within each cohort. This is an appropriate analytic choice when relationships are not expected to be linear across the life course.
Key Findings
Adiposity: younger adults generally had higher BMI
In three of the four studies, BMI decreased with increasing age among people with type 2 diabetes; ICMR-INDIAB was the exception. The overall signal is clinically intuitive and important: younger adults with diabetes in many settings appear more obese than their older counterparts.
This finding supports the view that younger-onset type 2 diabetes is often embedded in a phenotype of severe adiposity and insulin resistance. Because excess adiposity also drives nonalcoholic fatty liver disease, sleep apnea, inflammation, and cardiometabolic clustering, its significance extends beyond body weight alone.
Lipids: a more atherogenic pattern in younger adults
Younger adults had higher LDL cholesterol in NHANES and AusDiab, and lower HDL cholesterol in all studies except ICMR-INDIAB. Triglycerides were highest in younger adults and declined with age in AusDiab, NHANES, and the Mauritius Survey.
Of these findings, triglycerides may be especially informative. Hypertriglyceridemia is a hallmark of insulin resistance and often coexists with low HDL cholesterol and small dense LDL particles, a lipid pattern associated with accelerated atherosclerosis. The consistency of the triglyceride signal across three large cohorts strengthens the argument that younger adults with diabetes often have a more adverse metabolic profile despite being earlier in the life course.
Glycemia: fasting glucose and HbA1c peaked in midlife rather than old age
The glycemic findings were more nuanced than a simple age gradient. In AusDiab, the Mauritius Survey, and ICMR-INDIAB, fasting plasma glucose increased with age up to approximately 45 to 55 years and then declined. In NHANES, younger individuals with diabetes had higher fasting plasma glucose than older individuals.
Across all four studies, HbA1c increased with age, peaking around 50 to 60 years, before declining. Among those with newly diagnosed diabetes, 2-hour plasma glucose did not vary across age.
These patterns suggest that among adults living with type 2 diabetes, maximal glycemic exposure may be concentrated in early to mid-adulthood rather than in the oldest age groups. Several explanations are possible: survivor bias, treatment intensification in older adults, selective diagnosis patterns, or physiologic heterogeneity of diabetes across ages. Regardless of mechanism, the results argue against assuming that older age automatically means worse glycemia within the diabetic population.
Blood pressure and kidney injury: higher in older adults
In all four studies, systolic blood pressure and urinary albumin/creatinine ratio were higher in older adults. This pattern is expected and clinically meaningful. Arterial stiffening, cumulative vascular injury, chronic kidney disease, and longer exposure to hypertension all contribute to rising systolic pressure and albuminuria with age.
The implication is that the dominant complication pathways may shift across the lifespan. Younger adults may carry more obesity-driven and dyslipidemia-driven risk, while older adults show stronger signals of hemodynamic and renal injury.
How diabetes differed from normal glucose tolerance across age
One of the most informative analyses compared adults with diabetes against those with normal glucose tolerance. In most cohorts, the differences in fasting plasma glucose, HbA1c, triglycerides, and diastolic blood pressure were greater at younger than at older ages. Similar age-related attenuation was seen for BMI and systolic blood pressure in AusDiab and NHANES.
This means that diabetes, relative to age-matched metabolically normal peers, appears to impose a larger metabolic disturbance in younger adults. Stated differently, a 35-year-old with type 2 diabetes may be farther from the expected physiologic baseline for that age than a 75-year-old with type 2 diabetes is from theirs. That concept is highly relevant for risk communication and for long-term prevention strategies.
Clinical Interpretation
Why younger-onset diabetes may be especially hazardous
The study strengthens the argument that the excess complication risk seen in younger adults with type 2 diabetes is not explained only by longer duration. A phenotype of higher BMI, hypertriglyceridemia, lower HDL cholesterol, and marked glycemic abnormality relative to peers likely adds independent risk.
This aligns with prior longitudinal observations that young-onset type 2 diabetes is associated with rapid beta cell decline, early need for treatment intensification, and disproportionate lifetime cardiovascular burden. The present analysis does not measure outcomes directly, but it provides a plausible risk-factor framework for why those outcomes occur.
Implications for cardiovascular prevention
Traditional short-term cardiovascular risk calculators are heavily age weighted. As a result, younger adults with diabetes may appear deceptively low risk despite carrying severe metabolic abnormalities. These data support a more lifetime-oriented prevention model, emphasizing early weight management, aggressive lipid optimization, and prompt glycemic control rather than waiting for risk to become numerically high with age.
The lipid findings are particularly notable in this regard. Elevated triglycerides and low HDL cholesterol often indicate residual cardiometabolic risk even when LDL cholesterol is addressed. Although therapeutic decisions must follow guideline-based risk assessment, clinicians should be alert to the broader dyslipidemic context in younger patients.
Implications for renal and vascular protection in older adults
In contrast, higher systolic blood pressure and albuminuria in older adults underscore the central importance of kidney and vascular protection later in life. This supports careful blood pressure management, routine albuminuria screening, and use of renoprotective therapies where indicated and tolerated. The study does not test interventions, but its age-stratified patterns are consistent with current emphasis on individualized therapy based on predominant risk domains.
Mechanistic Considerations
Several biological mechanisms could underlie the observed age patterns. Younger adults with type 2 diabetes may have more severe insulin resistance, greater visceral adiposity, more hepatic overproduction of triglyceride-rich lipoproteins, and a stronger inflammatory phenotype. Social and behavioral factors may also contribute, including lower rates of treatment adherence, less frequent healthcare engagement, delayed intensification, and competing work or family responsibilities.
By contrast, in older adults, age-related arterial stiffness, nephron loss, endothelial dysfunction, and cumulative exposure to hypertension may drive the rise in systolic blood pressure and albuminuria. Declining HbA1c at older ages may reflect treatment selection, frailty-related weight loss, survival bias, or a cohort effect rather than true reduction in disease severity.
Strengths and Limitations
Strengths
The study’s major strengths are its multinational scope, large overall sample size, and inclusion of ethnically and economically diverse populations. Using multiple cohorts allows assessment of whether age-related patterns are consistent across settings rather than being specific to a single health system or ancestry group.
The inclusion of people with normal glucose tolerance is another important strength because it contextualizes diabetes-related abnormalities against an age-matched non-diabetic reference.
Limitations
The analysis is cross-sectional, so it cannot establish causality or determine how individual risk factors evolve over time. Age differences may reflect cohort effects, survival bias, treatment practices, or selective participation, rather than pure aging effects within the same person.
The abstract does not provide effect sizes, confidence intervals, or detailed covariate adjustment in the summary available here, which limits granular interpretation of magnitude. Definitions of diabetes and measurements may also vary somewhat across surveys, and medication use, duration of diagnosed diabetes, socioeconomic factors, and access to care may differ importantly between countries.
In addition, ICMR-INDIAB differed from the other studies in some lipid and BMI patterns, reminding readers that age-related cardiometabolic phenotypes are not universally identical across populations.
Practice Takeaways
For clinicians, the central message is that age in type 2 diabetes should not be interpreted simplistically. Younger adults may have lower systolic blood pressure and less albuminuria than older adults, but they often show greater obesity and more adverse lipid and glycemic patterns relative to peers. That combination may translate into substantial lifetime risk if undertreated.
In practical terms, younger-onset type 2 diabetes should prompt careful assessment of weight trajectory, triglycerides, HDL cholesterol, and sustained glycemic exposure, alongside traditional LDL cholesterol and blood pressure management. For older adults, vigilance for albuminuria, isolated systolic hypertension, and chronic kidney disease remains essential.
These findings also support age-tailored communication. Younger patients may respond better when clinicians explain that “low 10-year risk” does not mean “low lifetime risk,” particularly when marked metabolic derangements are already present.
Conclusion
This multinational analysis shows that cardiometabolic risk in type 2 diabetes is patterned by age in clinically meaningful ways. Younger adults generally carried higher BMI and triglycerides, and often a more adverse lipid profile, while fasting glucose and HbA1c peaked in midlife. Older adults, by contrast, had higher systolic blood pressure and urinary albumin/creatinine ratio.
Perhaps the most important insight is comparative: relative to adults with normal glucose tolerance, the metabolic disruption associated with diabetes was often more pronounced at younger ages. These findings help explain why younger-onset type 2 diabetes can be so hazardous and reinforce the need for earlier, more intensive, and more individualized cardiometabolic risk reduction.
Future longitudinal studies should determine how these age-specific risk-factor constellations translate into retinopathy, nephropathy, cardiovascular events, heart failure, and mortality, and whether intervention strategies should be explicitly calibrated to age at onset or age at assessment.
Funding and ClinicalTrials.gov
Funding details were not provided in the abstract summarized here. ClinicalTrials.gov registration is not applicable or was not reported, as this was a cross-sectional analysis of established national survey cohorts rather than an interventional clinical trial.
References
Sajjadi SF, Sacre JW, Kowlessur S, Soderberg S, Zimmet PZ, Tuomilehto J, Deepa M, Pradeepa R, Anjana RM, Mohan V, Shaw JE, Magliano DJ. Age-related patterns of cardiometabolic risk factors for complications in type 2 diabetes. Diabetologia. 2026-05-22. PMID: 42171728.
American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes—2025. Diabetes Care. 2025;48(Suppl 1).
Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2022;65:1925-1966.
Hillier TA, Pedula KL. Complications in young adults with early-onset type 2 diabetes: losing the relative protection of youth. Diabetes Care. 2003;26(11):2999-3005.
TODAY Study Group. Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care. 2013;36(6):1735-1741.
